7MJ7

HLA-A*02:01 bound to Neuroblastoma Derived IGFBPL1 peptide

Summary for 7MJ7

• Entry DOI: 10.2210/pdb7mj7/pdb
• Descriptor: MHC class I antigen, Beta-2-microglobulin, Insulin-like growth factor-binding protein-like 1 peptide, ... (5 entities in total)
• Functional Keywords: neuroblastoma tumor antigen, igfbpl1, human major histocompatibility complex class i, mhc-i, complex, immune system
• Biological source: Homo sapiens (Human); More
• Total number of polymer chains: 3
• Total formula weight: 45226.46

Authors

Toor, J.S.,Tripathi, S.M.,Truong, H.V.,Yarmarkovich, M.,Maris, J.M.,Sgourakis, N.G. (deposition date: 2021-04-19, release date: 2021-08-18, Last modification date: 2024-10-09)

Primary citation

Yarmarkovich, M.,Marshall, Q.F.,Warrington, J.M.,Premaratne, R.,Farrel, A.,Groff, D.,Li, W.,di Marco, M.,Runbeck, E.,Truong, H.,Toor, J.S.,Tripathi, S.,Nguyen, S.,Shen, H.,Noel, T.,Church, N.L.,Weiner, A.,Kendsersky, N.,Martinez, D.,Weisberg, R.,Christie, M.,Eisenlohr, L.,Bosse, K.R.,Dimitrov, D.S.,Stevanovic, S.,Sgourakis, N.G.,Kiefel, B.R.,Maris, J.M.
Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs.
Nature, 599:477-484, 2021

PubMed Abstract: The majority of oncogenic drivers are intracellular proteins, thus constraining their immunotherapeutic targeting to mutated peptides (neoantigens) presented by individual human leukocyte antigen (HLA) allotypes. However, most cancers have a modest mutational burden that is insufficient to generate responses using neoantigen-based therapies. Neuroblastoma is a paediatric cancer that harbours few mutations and is instead driven by epigenetically deregulated transcriptional networks. Here we show that the neuroblastoma immunopeptidome is enriched with peptides derived from proteins that are essential for tumourigenesis and focus on targeting the unmutated peptide QYNPIRTTF, discovered on HLA-A*24:02, which is derived from the neuroblastoma dependency gene and master transcriptional regulator PHOX2B. To target QYNPIRTTF, we developed peptide-centric chimeric antigen receptors (CARs) using a counter-panning strategy with predicted potentially cross-reactive peptides. We further hypothesized that peptide-centric CARs could recognize peptides on additional HLA allotypes when presented in a similar manner. Informed by computational modelling, we showed that PHOX2B peptide-centric CARs also recognize QYNPIRTTF presented by HLA-A*23:01 and the highly divergent HLA-B*14:02. Finally, we demonstrated potent and specific killing of neuroblastoma cells expressing these HLAs in vitro and complete tumour regression in mice. These data suggest that peptide-centric CARs have the potential to vastly expand the pool of immunotherapeutic targets to include non-immunogenic intracellular oncoproteins and widen the population of patients who would benefit from such therapy by breaking conventional HLA restriction.

PubMed: 34732890
DOI: 10.1038/s41586-021-04061-6

Experimental method

X-RAY DIFFRACTION (1.6 Å)